Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) EBIT Margin (2016 - 2026)

United Therapeutics' EBIT Margin history spans 17 years, with the latest figure at 45.14% for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 347.0% to 45.14% in Q4 2025 year-over-year; TTM through Dec 2025 was 46.89%, a 96.0% decrease, with the full-year FY2025 number at 46.89%, down 96.0% from a year prior.
  • EBIT Margin hit 45.14% in Q4 2025 for United Therapeutics, down from 48.59% in the prior quarter.
  • Over the last five years, EBIT Margin for UTHR hit a ceiling of 62.35% in Q1 2022 and a floor of 17.09% in Q1 2021.
  • Historically, EBIT Margin has averaged 45.56% across 5 years, with a median of 48.39% in 2025.
  • Biggest five-year swings in EBIT Margin: plummeted -6388bps in 2021 and later skyrocketed 7944bps in 2022.
  • Tracing UTHR's EBIT Margin over 5 years: stood at 40.9% in 2021, then decreased by -13bps to 35.73% in 2022, then increased by 18bps to 42.31% in 2023, then rose by 15bps to 48.61% in 2024, then dropped by -7bps to 45.14% in 2025.
  • Business Quant data shows EBIT Margin for UTHR at 45.14% in Q4 2025, 48.59% in Q3 2025, and 45.64% in Q2 2025.